Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CHKA | P35790 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.37 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14044902 | 0.98 | CA2 (0.48) | CA2CHKACHRM2CHRM1CHRM3 | |
| SCHEMBL28950008 | 0.96 | CA2 (0.50) | CA2CHKACHRM2CHRM1CHRM3 | |
| SCHEMBL3832932 | 0.93 | CA2 (0.47) | CA2CHKACHRM2CHRM1CHRM3 | |
| SCHEMBL3100695 | 0.90 | CA2 (0.46) | CA2CHKACHRM2CHRM1CHRM3 | |
| SCHEMBL696750 | 0.88 | CA2 (0.48) | CA2CHKACHRM2CHRM1CHRM3 | |
| SCHEMBL3827972 | 0.86 | CA2 (0.46) | CA2CHKACHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL6898768 | 0.86 | CA2 (0.46) | CA2CHKACHRM2CHRM1CHRM3 | |
| SCHEMBL3828888 | 0.86 | CA2 (0.46) | CA2CHKACHRM2CHRM1CHRM3 | |
| SCHEMBL8198901 | 0.84 | ALDH1A1 (0.46) | ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL22233151 | 0.82 | PKM (0.47) | CA2CHKACHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2022787-A1 | Process for the preparation of N-1 protected N ring nitrogen containing cyclic polyamines and products thereof | ANORMED INC. (CA) | 2009-02-11 | — | — | EP | claimed |
| US-12510524-B2 | Compositions containing cannabinoid analog conjugates and methods of use | VYRIPHARM ENTERPRISES, LLC (US) | 2025-12-30 | — | — | US | disclosed |
| US-20210080441-A1 | COMPOSITIONS CONTAINING CANNABINOID ANALOG CONJUGATES AND METHODS OF USE | VYRIPHARM ENTERPRISES, LLC (US) | 2021-03-18 | — | — | US | disclosed |
| US-20210080441-A1 | COMPOSITIONS CONTAINING CANNABINOID ANALOG CONJUGATES AND METHODS OF USE | VYRIPHARM ENTERPRISES, LLC (US) | 2021-03-18 | — | — | US | disclosed |
| US-10544109-B2 | Process for the preparation of xylene linked cyclam compounds | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2020-01-28 | — | — | US | disclosed |
| EP-3344608-B1 | A PROCESS FOR THE PREPARATION OF XYLENE LINKED CYCLAM COMPOUNDS | FRESENIUS KABI ONCOLOGY LTD (IN) | 2019-10-23 | — | — | EP | disclosed |
| WO-2019018536-A1 | COMPOSITIONS CONTAINING CANNABINOID ANALOG CONJUGATES AND METHODS OF USE | VYRIPHARM ENTERPRISES, LLC (US) | 2019-01-24 | — | — | WO | disclosed |
| WO-2017037639-A1 | A PROCESS FOR THE PREPARATION OF XYLENE LINKED CYCLAM COMPOUNDS | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2017-03-09 | — | — | WO | disclosed |
| WO-2014125499-A1 | IMPROVED AND COMMERCIALLY VIABLE PROCESS FOR THE PREPARATION OF HIGH PURE PLERIXAFOR BASE | NATCO PHARMA LIMITED (IN) | 2014-08-21 | — | — | WO | disclosed |
| US-8758723-B2 | Compositions and methods for cellular imaging and therapy | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-06-24 | — | — | US | disclosed |
| US-8758723-B2 | Compositions and methods for cellular imaging and therapy | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-06-24 | — | — | US | disclosed |
| EP-1322626-B1 | PROCESS FOR PREPARATION OF N-1 PROTECTED N RING NITROGEN CONTAINING CYCLIC POLYAMINES AND PRODUCTS THEREOF | ANORMED INC (CA) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008130439-A1 | COMPOSITIONS AND METHODS FOR CELLULAR IMAGING AND THERAPY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20070248537-A1 | Compositions and Methods for Cellular Imaging and Therapy | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2007-10-25 | — | — | US | disclosed |
| US-20070248537-A1 | Compositions and Methods for Cellular Imaging and Therapy | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12510524-B2 | Compositions containing cannabinoid analog conjugates and methods of use | CNR1, CNR2, CALM1 | CA2 2450/4885CHKA 144/4885CHRM2 13/4885 |
| US-10544109-B2 | Process for the preparation of xylene linked cyclam compounds | CXCR4, CXCR6, CXCR1 | CA2 3059/4885CHKA 1976/4885CHRM2 809/4885 |
| US-20070248537-A1 | Compositions and Methods for Cellular Imaging and Therapy | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCL, NME4 | CA2 1409/4885CHKA 455/4885CHRM2 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.